Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGART With ABC and SIVAB Plus Chemotherapy in Inoperable NSCLC
NCT02059967Phase 1Withdrawn
- Sponsor
- Virginia Commonwealth University
- Start
- Mar 2014
- Primary completion
- Jan 2015
01
Overview
Phase 1, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Virginia Commonwealth University. Primary endpoint: Maximum Tolerated Dose at 3 months. Planned start Mar 2014; status: withdrawn.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02059967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059967.